NASDAQ$TARS
Tarsus Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported third quarter results with a net loss of $15.7 million and advanced the clinical pipeline.
Tarsus Pharmaceuticals reported a net loss of $15.7 million for the third quarter of 2021. The company is on track to complete enrollment in the Saturn-2 Phase 3 trial for TP-03 by the end of the year and expects topline data in Q1 2022. They also continue to advance the Callisto Phase 1 trial of TP-05.
- On track to complete enrollment in Saturn-2 Phase 3 trial for TP-03 by year end 2021, with topline data expected in Q1 2022.
- Presented data from Titan and Atlas studies on the prevalence and impact of Demodex blepharitis at the American Academy of Optometry 2021 Annual Meeting.
- Advanced the Callisto Phase 1 trial of TP-05 for the prevention of Lyme disease with data expected in the first half of 2022.
- Cash and equivalents of $183.8 million as of September 30, 2021, for expected runway into the second half of 2023.
Headline financials
Revenue & EPS history
Tarsus · Revenue · Quarterly
$1.24M
Forward guidance
Tarsus Pharmaceuticals anticipates significant advancements in its pipeline, including initiating TP-03 for Meibomian Gland Disease and TP-04 for rosacea in the first half of 2022. The company also expects to complete the Phase 1 trial of TP-05 for the prevention of Lyme disease and conduct further FDA discussions in the first half of 2022.
Tailwinds
- Initiating TP-03 for Meibomian Gland Disease in the first half of 2022.
- Initiating TP-04 for rosacea in the first half of 2022.
- Completing the Phase 1 trial of TP-05 for the prevention of Lyme disease in the first half of 2022.
- Conducting further FDA discussions in the first half of 2022.
- Expecting to earn an additional $15 million in clinical milestones in the first half of 2022 from LianBio partnership.
Headwinds
- Incurred significant losses and negative cash flows from operations since inception.
- May need to obtain additional funding to complete the development and any commercialization of its product candidates.
- Heavily dependent on the success of its lead product candidate, TP-03 for the treatment of Demodex blepharitis.
- COVID-19 pandemic may affect Tarsus’ ability to initiate and complete preclinical studies and clinical trials.
- May not be successful in educating healthcare professionals and the market about the need for treatments specifically for Demodex blepharitis, Lyme disease, and/or other diseases or conditions targeted by Tarsus’ products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+3.2%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+17.8%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+18.3%
Q2 2024
Best reaction
-10.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -8.4% | -9.0% | |
| Q4 2025 | +9.6% | +8.5% | -3.4% | |
| Q3 2025 | -4.7% | +1.8% | +14.4% | |
| Q1 2025 | -6.1% | -5.9% | -14.6% | |
| Q4 2024 | -9.3% | -2.3% | +11.2% | |
| Q3 2024 | -1.9% | -6.2% | +10.4% | |
| Q2 2024 | +18.3% | +16.5% | +34.8% | |
| Q1 2024 | -10.5% | +0.9% | -15.3% | |
| Q4 2023 | +14.2% | +11.4% | +9.6% | |
| Q3 2023 | +5.6% | +8.3% | +4.5% | |
| Q2 2023 | -2.5% | -1.5% | -7.0% | |
| Q1 2023 | +7.1% | +5.8% | +25.9% | |
| Q4 2022 | +0.4% | -10.6% | -15.8% | |
| Q3 2022 | -0.1% | -0.5% | -14.2% | |
| Q2 2022 | +5.4% | +0.6% | -8.3% | |
| Q1 2022 | +7.2% | +16.8% | +25.4% | |
| Q4 2021 | -4.9% | -4.7% | -1.1% | |
| Q3 2021 | +0.4% | -2.9% | -13.8% | |
| Q2 2021 | +6.2% | +3.7% | +13.3% | |
| Q1 2021 | +2.9% | +5.6% | +38.3% | |
| Q4 2020 | +16.4% | +15.8% | +8.6% | |
| Q1 2020 | +7.5% | +16.1% | +111.4% | |
| Q3 2020 | +7.5% | +16.1% | +111.4% | |
| Q2 2020 | +7.5% | +16.1% | +111.4% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro